Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XNW 5004

Next Previous
Drug Profile

XNW 5004

Alternative Names: XNW-5004

Latest Information Update: 21 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evopoint Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I/II Lymphoma; Prostate cancer; Solid tumours
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 30 May 2025 Efficacy and adverse events data from a phase I/II trial in Lymphoma presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 21 Jan 2025 Evopoint Biosciences plans a phase III trial in Peripheral T cell lymphoma (Second line therapy or greater; In infants; In neonates) (PO, Tablet) (NCT06776952)
  • 30 Nov 2024 Evopoint Biosciences plans a phase II trial for Peripheral T cell lymphoma (Second-line therapy or greater) (PO), in November 2024 (NCT06702605)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top